Avalo Therapeutics, Inc.
AVTX•NASDAQ•Healthcare•Biotechnology

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOGarry Neil
Founded2011
IPO DateOctober 15, 2015
Employees23
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.avalotx.com
Phone410 522 8707
Address
540 Gaither Road, Suite 400 Rockville, Maryland 20850 United States

Corporate Identifiers

CIK0001534120
CUSIP05338F108
ISINUS05338F3064
EIN45-0705648
SIC2834

Leadership Team & Key Executives

Dr. Garry A. Neil M.D.
President, Chief Executive Officer and Director
Christopher Ryan Sullivan CPA
Chief Financial Officer and Head of Investor relations
Dr. Mittie Doyle FACR, M.D.
Chief Medical Officer
Dr. Solomon H. Snyder M.D.
Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D.
Founder and Member of Scientific Advisory Board
Paul C. Varki J.D., M.P.H
Chief Legal Officer
Ashley Ivanowicz
Senior Vice President of Human Resources
Colleen Matkowski
Senior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Dino C. Miano Ph.D.
Senior Vice President of CMC and Technical Operations
Jennifer Riley
Chief Strategy Officer